Published 6 days ago • loading... • Updated 6 days ago

Mabwell Passes On-Site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the Fi

On Monday, April 20, Mabwell announced its wholly-owned subsidiary T-mab successfully passed an on-site GMP inspection by the Jordan Food and Drug Administration, receiving a 'Compliance' conclusion.
This marks Mabwell's inaugural recognition by a Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme member country, as Jordan's GMP standards align with high-level international regulatory requirements.
Auditors conducted a comprehensive review of Taizhou Mabwell facilities, equipment, quality systems, and production processes for two denosumab injections: a Prolia biosimilar and an Xgeva biosimilar.
Senior Vice President Huiguo Hu said, "Successfully passing this GMP inspection by a PIC/S member country demonstrates that Mabwell's quality management system is gaining increasing recognition," enhancing Middle East biologic accessibility.
Mabwell has reached strategic collaborations covering 33 countries for its denosumab injection products, having obtained marketing approval in Pakistan in 2025 to support global expansion.

Insights by Ground AI

31 Articles

The Berkshire Eagle

+29 Reposted by 29 other sources

Center

Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time

SHANGHAI, April 20, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-mab, has successfully passed the on-site GMP inspection conducted by the Jordan Food and Drug Administration (JFDA).…

6 days ago

Read Full Article